Febit Acquires License From OGT
News Nov 21, 2005
febit biotech gmbh has announced that it has acquired a license from Oxford Gene Technology (OGT) from Oxford, UK.
The acquired license refers to patents on technologies that were developed in the 80ies by OGT’s founder, Professor Edwin M. Southern.
The "Southern array patents" are the fundamental patents covering the manufacture and use of DNA microarrays in genetic and genomic research.
"We are delighted about the successful conclusion of the agreement with OGT, which further strengthens our IP position to successfully market our GENIOM® technology worldwide," says Cord F. Stahler, President & CEO of febit biotech gmbh.
Dr. Mike Evans, Chief Executive of OGT adds, "We are happy to support febit biotech’s technology by granting this license and thus further the use of microarray technology."
Scientists used a gene editing method called CRISPR/Cas9 to generate mice that faithfully mimic a fatal respiratory disorder in newborn infants that turns their lips and skin blue. The new laboratory model allowed researchers to pinpoint the ailment's cause and develop a potential and desperately needed nanoparticle-based treatment.READ MORE